Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estimulación de Vago Nervus y Parálisis cerebral

2 de noviembre de 2026 actualizado por: gulay karacaoglu, Istanbul Medipol University Hospital

Acute Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Autonomic Nervous System Regulation and Spasticity in Children With Spastic Cerebral Palsy: A Preliminary Study

This study investigated the acute effects of transcutaneous auricular vagus nerve stimulation (taVNS) on autonomic nervous system regulation and spasticity in children with spastic cerebral palsy. A total of 20 children aged 2-15 years participated in this prospective, single-group pretest-posttest study. All participants received a single 20-minute session of bilateral taVNS. Autonomic nervous system regulation was assessed using heart rate variability (HRV) parameters, while spasticity was evaluated using the Modified Ashworth Scale (MAS). Measurements were performed before and after the intervention to investigate the immediate effects of taVNS.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

This prospective, single-group pretest-posttest clinical study investigated the acute effects of transcutaneous auricular vagus nerve stimulation (taVNS) on autonomic nervous system regulation and spasticity in children with spastic cerebral palsy (CP). The study was conducted at the Physical Medicine and Rehabilitation Department of Bursa VM Medical Park Hospital, Türkiye, between January and March 2025.

A total of 20 children aged 2-15 years with a diagnosis of spastic cerebral palsy were included. All participants completed the study, and no dropouts occurred.

Assessment Procedures

Participants' demographic characteristics, including age, sex, height, weight, and body mass index, were recorded. Gross motor function was classified using the Gross Motor Function Classification System (GMFCS).

Spasticity was assessed using the Modified Ashworth Scale (MAS), which evaluates resistance to passive movement. Bilateral elbow flexors, wrist flexors, knee extensors, and ankle plantar flexors were assessed, resulting in eight individual scores per participant. The mean of these scores was used as the composite MAS score.

Autonomic nervous system regulation was evaluated through heart rate variability (HRV) measurements using the Elite HRV device. The recorded parameters included average heart rate, root mean square of successive differences (RMSSD), percentage of successive normal-to-normal intervals differing by more than 50 milliseconds (pNN50), low-frequency power (LF), high-frequency power (HF), and the LF/HF ratio.

HRV measurements were obtained during a one-minute recording period in the seated position with guided breathing.

Intervention

All participants received a single 20-minute session of bilateral transcutaneous auricular vagus nerve stimulation using the Vagustim device. Electrodes were positioned on the concha and tragus regions of both ears.

Stimulation was delivered using biphasic current at a frequency of 10 Hz and a pulse width of 300 microseconds. Stimulation intensity was gradually increased to the maximum comfortable level tolerated by each participant. The mean applied intensity was 0.8 ± 0.3 mA.

Participants were positioned supine during stimulation.

Assessment Timeline

Before the intervention, participants rested in a seated position for five minutes, followed by a one-minute HRV recording and MAS assessment.

Following the 20-minute taVNS session, participants returned to a seated position and rested for five minutes before the post-intervention HRV measurement. Spasticity was subsequently reassessed using the MAS.

The primary outcomes were changes in HRV parameters and spasticity following the single taVNS session.

Statistical Analysis

Data were analyzed using IBM SPSS Statistics version 28.0. Normality was assessed using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Paired-samples t-tests were used for normally distributed variables, while Wilcoxon signed-rank tests were applied to non-normally distributed variables. Spearman correlation analysis was performed to examine associations between GMFCS levels and changes in spasticity and autonomic nervous system parameters.

Statistical significance was set at p < 0.05.

All 20 participants completed the intervention and assessments, with no missing data or reported adverse events.

Tipo de estudio

Intervencionista

Inscripción (Actual)

20

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años a 15 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Children aged 2-15 years diagnosed with spastic cerebral palsy (CP) by a physical medicine and rehabilitation specialist or neurologist.

Written informed consent provided by parents or legal guardians and willingness of the child to participate.

Clinical stability without acute illness or comorbidities that could affect autonomic function or spasticity.

Exclusion Criteria:

Severe intellectual disability preventing understanding of or participation in study procedures.

Uncontrolled cardiovascular, respiratory, or autonomic disorders (e.g., arrhythmia or severe asthma).

Presence of medical devices potentially affected by vagus nerve stimulation (e.g., pacemakers or cochlear implants).

Risk of vagus nerve stimulation interacting with antiepileptic medication or triggering epileptic seizures.

Inability of the child or parent/legal guardian to comply with the study protocol or cooperate with study procedures.

Botulinum toxin injections within the previous three months.

Initiation or dose adjustment of oral antispastic medications (e.g., baclofen, tizanidine, or diazepam) within the previous month.

Initiation of a new rehabilitation program or intensification of an existing rehabilitation program within the previous four weeks.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: nervus vagus stimulation

All 20 participants received a single 20-minute session of bilateral transcutaneous auricular vagus nerve stimulation (taVNS) using the Vagustim device. Stimulation was delivered through electrodes positioned on the concha and tragus regions of both ears, using biphasic current at a frequency of 10 Hz and a pulse width of 300 microseconds. Stimulation intensity was gradually increased to the maximum comfortable level tolerated by each participant. Spasticity and heart rate variability (HRV) parameters were assessed before and after the intervention to evaluate its acute effects.

Transcutaneous auricular vagus nerve stimulation (taVNS) was administered bilaterally using the Vagustim device (Vagustim Medical Technologies, Istanbul, Türkiye). Participants received a single 20-minute stimulation session in the supine position. Electrodes were placed on the concha and tragus regions of both ears. Stimulation was delivered using biphasic current at a frequency of 10 Hz and a pulse width of 300 microseconds. The stimulation intensity was gradually increased to the maximum level tolerated by each participant. The mean applied stimulation intensity was 0.8 ± 0.3 mA (range: 0.4-1.5 mA).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Spasticity Assessed Using the Modified Ashworth Scale (MAS)
Periodo de tiempo: The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).

Spasticity was assessed using the Modified Ashworth Scale (MAS), which evaluates resistance to passive movement on a scale ranging from 0 (normal muscle tone) to 4 (complete rigidity). Bilateral elbow flexors, wrist flexors, knee extensors, and ankle plantar flexors were evaluated, yielding eight individual scores per participant. The mean of these eight scores was calculated as the composite MAS score. Higher scores indicated greater spasticity. Measurements were performed before and after the intervention to assess acute changes in spasticity following a single session of transcutaneous auricular vagus nerve stimulation (taVNS).

The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).
Autonomic Nervous System Activity Value/RMSSD
Periodo de tiempo: The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).

The autonomic nervous system cannot be directly evaluated through physiological tests. However, advancements in technology have introduced methods like heart rate variability (HRV) analysis, widely used in scientific research. HRV analysis measures RR waves during rest and will be employed in this study using the Elite HRV Corsense device. Key parameters include:

RMSSD: Reflects parasympathetic activity and forms the basis of HRV and and is expressed in milliseconds

The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).
Autonomic nervous system activity/ LF Power
Periodo de tiempo: The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).

The autonomic nervous system cannot be directly evaluated through physiological tests. However, advancements in technology have introduced methods like heart rate variability (HRV) analysis, widely used in scientific research. HRV analysis measures RR waves during rest and will be employed in this study using the Elite HRV Corsense device.LF Power: Indicates sympathetic activity (0.04-0.15 Hz range) and t is expressed as the square of milliseconds

The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).
Autonomic nervous system activity / HF Power
Periodo de tiempo: The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).

The autonomic nervous system cannot be directly evaluated through physiological tests. However, advancements in technology have introduced methods like heart rate variability (HRV) analysis, widely used in scientific research. HRV analysis measures RR waves during rest and will be employed in this study using the Elite HRV Corsense device.HF Power: Represents parasympathetic activity (0.15-0.40 Hz range) and t is expressed as the square of milliseconds

The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).
Autonomic nervous system activity - LF/HF
Periodo de tiempo: The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).

The autonomic nervous system cannot be directly evaluated through physiological tests. However, advancements in technology have introduced methods like heart rate variability (HRV) analysis, widely used in scientific research. HRV analysis measures RR waves during rest and will be employed in this study using the Elite HRV Corsense device.LF/HF Ratio: Measures sympathovagal balance.

The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).
Heart Rate
Periodo de tiempo: The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).

HRV analysis measures RR waves during rest and will be employed in this study using the Elite HRV Corsense device.The participants' average heart rate will be recorded in beats per minute (bpm).

The assessments will be conducted before and immediately after the application of vagus nerve stimulation (VNS).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de enero de 2025

Finalización primaria (Actual)

15 de marzo de 2025

Finalización del estudio (Actual)

31 de marzo de 2025

Fechas de registro del estudio

Enviado por primera vez

10 de marzo de 2025

Primero enviado que cumplió con los criterios de control de calidad

17 de marzo de 2025

Publicado por primera vez (Actual)

18 de marzo de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de enero de 2025

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir